Joan Bladé

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials

Stefano Pasquali, J D Maqueo, Jorge Espino Vela et al. · Oxford University Research Archive (ORA) (University of Oxford) · 1998 · 473 citations

Hematological Malignancy, Oncology, Metronomic Therapy +6

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

Bruno Paiva, María‐Belén Vídriales, Jorge Cerveró et al. · Blood · 2008 · 463 citations · Full text

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

Juan José Lahuerta, Bruno Paiva, María‐Belén Vídriales et al. · Journal of Clinical Oncology · 2017 · 305 citations · Full text

Hematological Malignancy, Prognostic Evaluation, Mrd Negativity +13

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

Bruno Paiva, Norma C. Gutiérrez, Laura Rosiñol et al. · Blood · 2011 · 303 citations · Full text

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

Bruno Paiva, Noemí Puig, María‐Teresa Cedena et al. · Journal of Clinical Oncology · 2019 · 261 citations · Full text